As Mipasetamab uzoptirine moves closer to clinical approval, what is the likelihood that the drug will be approved?

Mipasetamab uzoptirine is under clinical development by ADC Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Mipasetamab uzoptirine’s likelihood of approval (LoA) and phase transition for Bladder Cancer took place on 02 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 02 Aug 2022 increased Mipasetamab uzoptirine’s Phase Transition Success Rate (PTSR) for Bone Sarcoma, increased PTSR for Osteosarcoma, increased PTSR for Peritoneal Cancer, increased PTSR for Synovial Sarcoma, increased LoA and PTSR for Cervical Cancer, increased LoA and PTSR for Endometrial Cancer, increased PTSR for Ewing Sarcoma, increased PTSR for Fallopian Tube Cancer, increased LoA and PTSR for Leiomyosarcoma, and increased LoA and PTSR for Liposarcoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Mipasetamab uzoptirine LoA and PTSR Report.

Mipasetamab uzoptirine overview

ADCT-601(BGB-601) is under development for the treatment of solid tumor, renal cell carcinoma. The drug candidate is an antibody drug conjugate conjugated using glycoconnect technology comprises of monoclonal antibody with a pyrrolobenzodiazepines (PBD) based warheads. The therapeutic candidate is administered through intravenous route. It is developed based on pyrrolobenzodiazepine (PBD) warhead technology. This technology develops antibody drug conjugated by linking pyrrolobenzodiazepine (PBD) dimers with tumor specific antibody. It acts by targeting cells expressing tyrosine protein kinase receptor UFO. It is also under development for relapsed and refractory  triple-negative breast cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma, nasopharyngeal cancer, mesothelioma, non-small cell lung cancer, ovarian cancer, soft tissue sarcomas, leiomyosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma, synovial sarcoma, bone sarcoma: Ewing’s sarcoma, osteosarcoma, chondrosarcoma, fallopian tube cancer, primary peritoneal cancer, bladder cancer, cervical cancer, endometrial cancer and pancreatic cancer.

ADC Therapeutics overview

ADC Therapeutics, is a biotechnology company focused on the development and commercialization of antibody-drug conjugates (ADCs) to treat solid tumors and hematological cancers. It is investigating Loncastuximab Tesirine (Lonca), an ADC composed of a humanized monoclonal antibody against B-cell hematological tumors; and Camidanlumab Tesirine (Cami) for the treatment of solid tumors. It is also developing ADCT-602 drug for B-cell acute lymphoblastic leukemia; ADCT-601 targeting AXL in solid tumors; ADCT-901 against ovarian, triple-negative breast cancer and advanced solid tumors; and ADCT-701 drug targeting DLK-1 in neuroblastoma, hepatocellular carcinoma, small cell lung cancer, and acute myeloid leukemia. The company is a spin-off from Spirogen Ltd. ADC Therapeutics is headquartered in Lausanne, Switzerland.

Quick View Mipasetamab uzoptirine LOA Data